Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update

TORRANCE, Calif.–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the second quarter 2020 financial results and provided a general business update. “We are very happy to have concluded the reverse merger on June 15th and in that process, brought on a very well-respected group of […]